NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $48.60.

Several equities research analysts have recently commented on NAMS shares. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Needham & Company LLC lifted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th.

Insider Buying and Selling

In related news, insider Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the transaction, the insider owned 69,302 shares of the company’s stock, valued at $2,099,157.58. This trade represents a 59.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the transaction, the director directly owned 10,360 shares in the company, valued at $315,151.20. The trade was a 81.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 333,338 shares of company stock valued at $10,431,629 in the last 90 days. 12.74% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its stake in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares in the last quarter. Wells Fargo & Company MN lifted its stake in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. KBC Group NV bought a new position in NewAmsterdam Pharma in the first quarter valued at approximately $37,000. Navalign LLC bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $46,000. Finally, Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $85,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $32.11 on Thursday. NewAmsterdam Pharma has a one year low of $17.63 and a one year high of $42.21. The company has a 50 day moving average of $33.46 and a 200-day moving average of $34.03. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of -17.94 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million for the quarter. Equities research analysts anticipate that NewAmsterdam Pharma will post -1.76 earnings per share for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.